Checkpoint Therapeutics, Inc. (CKPT): Price and Financial Metrics

Checkpoint Therapeutics, Inc. (CKPT): $2.58

0.00 (0.00%)

POWR Rating

Component Grades

Momentum

D

Stability

D

Sentiment

Quality

D

CKPT Price/Volume Stats

Current price $2.58 52-week high $3.62
Prev. close $2.58 52-week low $1.30
Day low $2.47 Volume 246,100
Day high $2.65 Avg. volume 471,649
50-day MA $2.01 Dividend yield N/A
200-day MA $2.01 Market Cap 92.07M

CKPT Stock Price Chart Interactive Chart >


Checkpoint Therapeutics, Inc. (CKPT) Company Bio


Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of non-chemotherapy and immune-enhanced combination treatments for patients with solid tumor cancers. The company was founded in 2014 and is based in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.


CKPT Latest News Stream


Event/Time News Detail
Loading, please wait...

CKPT Latest Social Stream


Loading social stream, please wait...

View Full CKPT Social Stream

Latest CKPT News From Around the Web

Below are the latest news stories about CHECKPOINT THERAPEUTICS INC that investors may wish to consider to help them evaluate CKPT as an investment opportunity.

Checkpoint Therapeutics, Inc.'s (NASDAQ:CKPT) Profit Outlook

We feel now is a pretty good time to analyse Checkpoint Therapeutics, Inc.'s ( NASDAQ:CKPT ) business as it appears the...

Yahoo | December 19, 2023

UPDATE 1-US FDA declines to approve Checkpoint Therapeutics' skin cancer therapy

Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration declined to approve its experimental therapy to treat a type of advanced skin cancer, citing issues related to a third-party contract manufacturer. Checkpoint said the FDA did not state any concerns about the data or safety on the drug in its so-called complete response letter.

Yahoo | December 18, 2023

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimabWALTHAM, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), today announced that the U.S. Food and Drug Administration (“FDA”) has issued a complete response letter (“CRL”) for the cosibelimab biologic license application (“BLA”) for the treatment of patients with metastatic or locally advanced cutaneous squamous cell carcinoma

Yahoo | December 18, 2023

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

Some of the most explosive opportunities can be found in biotech stocks.

Ian Cooper on InvestorPlace | December 11, 2023

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No. 11,834,505) covering a method of treating various cancers, including cutaneous squamous cell carcinoma (“cSCC

Yahoo | December 5, 2023

Read More 'CKPT' Stories Here

CKPT Price Returns

1-mo 36.51%
3-mo 76.71%
6-mo 40.22%
1-year -24.34%
3-year -91.28%
5-year -90.72%
YTD 12.66%
2023 -55.19%
2022 -83.57%
2021 17.36%
2020 54.07%
2019 -5.49%

Continue Researching CKPT

Here are a few links from around the web to help you further your research on Checkpoint Therapeutics Inc's stock as an investment opportunity:

Checkpoint Therapeutics Inc (CKPT) Stock Price | Nasdaq
Checkpoint Therapeutics Inc (CKPT) Stock Quote, History and News - Yahoo Finance
Checkpoint Therapeutics Inc (CKPT) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!